HOPKINTON, Mass., April 16 /PRNewswire-FirstCall/ -- Boston Life Sciences (Nasdaq: BLSI - News) announced today that clinical data on its lead nerve repair therapy, Cethrin®, were presented in the Neurotrauma and Critical Care Scientific Session at the 75th Annual Meeting of the American Association of Neurological Surgeons (AANS) in Washington, DC.
